SCHEMBL1893465

SCHEMBL1893465

O=c1[nH]c2c(sc3ccc([N+](=O)[O-])cc32)c(=O)n1O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ERCC5 P28715 1/20 0.60
▸ FEN1 P39748 1/20 0.60
▸ CA12 O43570 3/20 0.59
▸ CA9 Q16790 3/20 0.59
▸ MAPT P10636 3/20 0.57
▸ SMN1; SMN2 Q16637 2/20 0.56
▸ LMNA P02545 1/20 0.56
▸ HTT P42858 1/20 0.56
▸ TDP1 Q9NUW8 1/20 0.56
▸ GLA P06280 1/20 0.48
▸ RECQL P46063 1/20 0.48
▸ G6PD P11413 1/20 0.41
▸ TLR9 Q9NR96 1/20 0.41
▸ MIF P14174 1/20 0.40
▸ PARP1 P09874 2/20 0.39
▸ CRHBP P24387 1/20 0.38
▸ CRHR2 Q13324 1/20 0.38
▸ POLB P06746 2/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1884682 0.76 FEN1 (1.00) ERCC5FEN1CA12CA9MAPT
SCHEMBL1884371 0.71 MAPT (0.51) MAPTSMN1; SMN2LMNAHTTTDP1
SCHEMBL13698355 0.70 EGFR (0.47) MAPTSMN1; SMN2LMNAHTTTDP1
SCHEMBL11118149 0.69 SMN1; SMN2 (0.50) MAPTSMN1; SMN2LMNAHTTTDP1
SCHEMBL1888480 0.69 RXFP1 (0.54) MAPTMEN1KMT2A
SCHEMBL11537464 0.68 PARP1 (0.55) CA12CA9MAPTSMN1; SMN2LMNA
SCHEMBL16857506 0.66 EGFR (0.50) MAPTSMN1; SMN2LMNAHTTG6PD
SCHEMBL4207679 0.66 PIM1 (0.67) MAPTSMN1; SMN2LMNAHTTTDP1
SCHEMBL11664475 0.65 MAPT (0.51) MAPTSMN1; SMN2LMNAHTTTDP1
SCHEMBL4208072 0.64 PARP1 (0.57) CA12CA9MAPTSMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7947691-B2 Cyclic n-hydroxy imides as inhibitors of flap endonuclease and uses thereof ATHERSYS, INC. (US) 2011-05-24 — — US claimed
US-20080287465-A1 Cyclic N-Hydroxy Imides as Inhibitors of Flap Endonuclease and Uses Thereof ATHERSYS, INC. (US) 2008-11-20 — — US claimed
WO-2006014647-A2 CYCLIC N-HYDROXY IMIDES AS INHIBITORS OF FLAP ENDONUCLEASE AND USES THEREOF ATHERSYS, INC. (US) 2006-02-09 — — WO claimed
US-7947691-B2 Cyclic n-hydroxy imides as inhibitors of flap endonuclease and uses thereof ATHERSYS, INC. (US) 2011-05-24 — — US disclosed
US-7947691-B2 Cyclic n-hydroxy imides as inhibitors of flap endonuclease and uses thereof ATHERSYS, INC. (US) 2011-05-24 — — US disclosed
US-20080287465-A1 Cyclic N-Hydroxy Imides as Inhibitors of Flap Endonuclease and Uses Thereof ATHERSYS, INC. (US) 2008-11-20 — — US disclosed
US-20080287465-A1 Cyclic N-Hydroxy Imides as Inhibitors of Flap Endonuclease and Uses Thereof ATHERSYS, INC. (US) 2008-11-20 — — US disclosed
WO-2006014647-A2 CYCLIC N-HYDROXY IMIDES AS INHIBITORS OF FLAP ENDONUCLEASE AND USES THEREOF ATHERSYS, INC. (US) 2006-02-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287465-A1 Cyclic N-Hydroxy Imides as Inhibitors of Flap Endonuclease and Uses Thereof FEN1, UNG, POLH ERCC5 73/4885FEN1 1/4885CA12 2881/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback